In this study, our findings indicated that high-m6Arisk group appeared to coexist with high expression levels of common immune checkpoint molecules (such as CTLA-4, PDCD1(PD-1), and TIGIT), indirectly suggesting that m6Arisk score may be a better predictor of immunotherapy in HCC patients. Here, TIGIT is linked to hepatocellular carcinoma.